UK-based pharmaceutical company Astrazeneca reported $25.4 billion in revenues in its 3Q21 earnings report, up 28% from 2020. A $2.2 billion dollar windfall in COVID vaccine revenues accounted for 11% of the rise in total revenues with the remaining 17% of growth coming from other medicines.
Gains in oncology which was up 16%, cardiovascular, renal and metabolism which was up 10% and respiratory and immunology which was up 12% accounted for the rest of the revenue rise over 2021.
According to the company it had released 1.5 billion doses of Vaxzevria, its COVID-19 vaccine, for global supply as of the end of September of which more than 145 million was distributed to the COVAX collaboration led by the WHO to ensure the availability of vaccines in low-income countries.
The company reported that one of its trial drugs, AZD7442, has had multiple positive Phase III results for COVID prevention and treatment, showing a 77% reduction of risk of symptomatic COVID-19 and a 50% risk reduction at 7 days from the disease’s onset. Astrazeneca also noted that Vaxzevria offers 91% protection against death due to the Delta variant.
Geographically growth was driven by the US market, which showed 53% year-over-year 3Q21 gains, flowed by Europe with 36% gains over the same period.